jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - кармустином - hodgkin disease; lymphoma, non-hodgkin - antineoplastična sredstva - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
d-cell 360 automated haematology analyzer
druŠtvo sa ograniČenom odgovornoŠĆu "farmalab" d.o.o. podgorica - in vitro dijagnostička medicinska sredstva
leflunomide medac
medac gesellschaft für klinische spezialpräparate mbh - leflunomid - artritis, reumatoidni - selektivni imunosupresivi - leflunomide indiciran za liječenje odraslih bolesnika s:aktivni reumatoidni artritis kao bolest-mijenjanje противоревматические lijekovi (dmards). najnovije ili istodobno liječenje гепатотоксичными ili haematotoxic lijekovima (e. metotreksatom) može dovesti do povećanog rizika od ozbiljnih nuspojava, pa se početak liječenja лефлуномидом potrebno je pažljivo razmotriti relativno tih koristi / aspekte rizika . osim toga, prebacivanje s лефлуномидом u drugi dmards bez vođenja postupka ispiranja također može povećati rizik od ozbiljnih nuspojava, čak i za dugo nakon komutacije.
vaxneuvance
merck sharp & dohme b.v. - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumococcal infekcije - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. pogledajte odjeljke 4. 4 i 5. 1 za informacije o zaštiti od specifičnih pneumokoknih serotipova. the use of vaxneuvance should be in accordance with official recommendations.
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastična sredstva - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
besponsa 1mg prašak za koncentrat za rastvor za infuziju
"evropa lek pharma" doo podgorica - inotuzumab ozogamicin - prašak za koncentrat za rastvor za infuziju - 1mg
trecondi
medac gesellschaft für klinische spezialpräparate mbh - treosulfan - transplantacija hematopoetskih matičnih stanica - antineoplastična sredstva - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
karmustin pliva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - karmustin - prašak i otapalo za koncentrat za otopinu za infuziju - 100 mg - urbroj: jedna bočica praška sadrži 100 mg karmustina
karmustin teva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju
teva b.v., swensweg 5, haarlem, nizozemska - karmustin - prašak i otapalo za koncentrat za otopinu za infuziju - 100 mg - urbroj: jedna bočica praška sadrži 100 mg karmustina